Image

Global RNAi Therapeutics Market – Industry Trends and Forecast to 2030

Healthcare

Image

Global RNAi Therapeutics Market – Industry Trends and Forecast to 2030

  • Healthcare
  • Upcoming Report
  • Nov 2022
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Global RNAi Therapeutics Market – Industry Trends and Forecast to 2030

Market Size in USD Billion

CAGR :  % Diagram

Diagram Forecast Period 2022–2030
Diagram Market Size (Base Year) USD 807.99 USD Million
Diagram Market Size (Forecast Year) USD 1,645.76 USD Million
Diagram CAGR %

Major Markets Players

  • Dummy1
  • Dummy2
  • Dummy3
  • Dummy4
  • Dummy5

Global RNAi Therapeutics Market, By Molecule Type (Small Interfering RNAS, Microrna), Application (Genetic Disorder, Oncology, Neurodegenerative Disorder, Cardiovascular Disorder, Respiratory Disorder, Infectious Disease, Renal Disease, Other), Route of Administration (Intradermal Injections, Pulmonary Delivery, Intravenous Injections, Intraperitoneal Injections, Others), End- User (Diagnostic Laboratories, Research and Academic Laboratories, Hospitals) – Industry Trends and Forecast to 2030.

RNAi Therapeutics Market

RNAi Therapeutics Market Analysis and Size

According to the World Health Organization estimates that cancer caused 9.6 million deaths in 2018 and is the second-highest cause of death worldwide. About 1 in 6 fatalities worldwide are caused by cancer. Over the following two decades, there will likely be a 70 percent increase in new cases. Additionally, recent developments have made it possible to overcome this barrier and facilitate the clinical use of RNAi-based therapeutics for cancer treatment.

Data Bridge Market Research analyses that the RNAi therapeutics market which was USD 807.99 million in 2022, would rocket up to USD 1645.76 million by 2030, and is expected to undergo a CAGR of 9.3% during the forecast period 2023 to 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

RNAi Therapeutics Market Scope and Segmentation  

Report Metric

Details

Forecast Period

2023 to 2030

Base Year

2022

Historic Years

2021 (Customizable to 2015 - 2020)

Quantitative Units

Revenue in USD Million, Volumes in Units, Pricing in USD

Segments Covered

Molecule Type (Small Interfering RNAS, Microrna), Application (Genetic Disorder, Oncology, Neurodegenerative Disorder, Cardiovascular Disorder, Respiratory Disorder, Infectious Disease, Renal Disease, Other), Route of Administration (Intradermal Injections, Pulmonary Delivery, Intravenous Injections, Intraperitoneal Injections, Others), End- User (Diagnostic Laboratories, Research and Academic Laboratories, Hospitals)

Countries Covered

U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

Market Players Covered

Quark Software Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Rexahn Pharmaceuticals, Inc. (U.S.), Silence Therapeutics (U.K.), Arbutus Biopharma (U.S.), Benitec Biopharma (Australia), GSK plc (U.K.), OLIX PHARMACEUTICALS, INC. (South Korea), Sanofi (France), Alnylam Pharmaceuticals, Inc. (U.S.), Moderna Inc. (U.S.), Ionis Pharmaceuticals (U.S.)

Market Opportunities

  • Increasing usage of RNAi therapeutics for the treatment of neurodegenerative disorders
  • Rising rates of chronic diseases like cancer

Market Definition

A brand-new class of drugs based on ribonucleic acid is known as RNA therapies (RNA). Target mRNA molecules are neutralized during the biological process known as RNA interference, and RNA molecules are then shown to impede gene expression or translation. Additionally, RNA interference (RNAi) is a group of short RNA-directed processes that inhibits the expression of genes in a sequentially-specific manner.

RNAi Therapeutics Market Dynamics

Drivers

  • Rising cases of chronic diseases

The rising rates of chronic diseases like cancer, cardiovascular conditions, and others will accelerate market expansion. The RNAi therapeutics market will be further fuelled by additional factors such as rising RNAi therapeutic approvals, advancements in the healthcare sector, rising R&D expenditures, and rising pharmaceutical company collaborations during the forecast period of 2023 to 2030.

  • Increasing collaborative activities

The increasing collaboration activities between drug distribution companies and contract research organizations (CROs) contribute to the growth of the RNAi therapeutics market. Arrowhead Pharmaceuticals Inc and Horizon Therapeutics plc announced a global collaboration and licence agreement for ARO-XDH, a previously undisclosed discovery-stage investigational RNA interference (RNAi) therapeutic being developed by Arrowhead as a potential treatment for people with uncontrolled gout, on June 21, 2021. This collaboration with Horizon also represents an expansion of Arrowhead Pharmaceuticals' rapidly growing pipeline of investigational RNAi therapeutics based on the company's proprietary Targeted RNAi Molecule (TRiMTM) platform." In January 2016, Ionis Pharmaceuticals (previously Isis Pharmaceuticals) began a Phase-I study of ISIS-HBV-L Rx in collaboration with GSK Pharmaceuticals. This acquisition aims to treat Hepatitis B viral infection.

Opportunities

  • Increasing use of RNAi therapeutics

Increasing usage of RNAi therapeutics for the treatment of neurodegenerative disorders is expected to create new opportunities for the market. For instance, Silence Therapeutics' mRNAi GOLD platform is designed to deliver gene-silencing medicine to specific liver cells in the body by combining siRNA molecules with chemical address tags called GaINAc, a naturally occurring sugar that binds specifically to liver cells. These RNAi molecules can then enter liver cells and silence disease-associated genes that are expressed there.

Restraints/Challenges

  • High investment and strict regulations

FDA drug approval rates have been declining in recent years. Obtaining FDA approval for a new drug has become extremely difficult. It has approved fewer than half as many new drugs in 2016 (19 so far) as it did in 2015 (45 total) and 2014. (41 total). As a result, despite large investments, the number of innovative drugs manufactured has decreased. The FDA cites manufacturing standards and other compliance issues as the primary causes of this downward trend. This can hamper the growth of RNAi therapeutics, especially since miRNAs and siRNAs fall into the relatively new field of genetic medicine, which may necessitate more intensive clinical trials.

This RNAi therapeutics market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the RNAi therapeutics market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on RNAi Therapeutics Market

COVID-19 pandemic has positively impacted the market due to the growing relevance of RNA-based investigations and increasing funding for R&D activities. Numerous businesses are investing resources to test diseases that have undergone constant improvement in genomic and molecular understanding to take advantage of opportunities fuelling market growth. As an illustration, in August 2020, Pediatrix Medical Group and GeneDx Inc., a division of BioReference Laboratories Inc., reached an agreement to provide cutting-edge, next-generation genomic sequencing to enable the clinical identification of uncommon disorders for newborn intensive care units.

Recent Development

  • On February 26, 2020, The Brazilian Health Regulatory Agency (ANVISA) approved ONPATTRO for treating hereditary transthyretin-mediated (hATTR) amyloidosis in adults, according to a prominent company's announcement.
  • In June 2020, OliX Pharmaceuticals and LGC Biosarch Technology agreed to quicken the manufacturing of asymmetric siRNA for treating wet macular degeneration and subretinal fibrosis.

Global RNAi Therapeutics Market Scope

The RNAi therapeutics market is segmented on the basis of molecule type, application, route of administration and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Molecule Type

  • Small Interfering RNAS
  • Microrna

Application

  • Genetic Disorder
  • Oncology
  • Neurodegenerative Disorder
  • Cardiovascular Disorder
  • Respiratory Disorder
  • Infectious Disease
  • Renal Disease
  • Other

 Route of Administration

  • Intradermal Injections
  • Pulmonary Delivery
  • Intravenous Injections
  • Intraperitoneal Injections
  • Others

End-User

  • Diagnostic Laboratories
  • Research and Academic Laboratories
  • Hospitals

RNAi Therapeutics Market Regional Analysis/Insights

The RNAi therapeutics market is analyzed and market size insights and trends are provided by country, molecule type, application, route of administration and end-user as referenced above.

The countries covered in the RNAi therapeutics market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the RNAi therapeutics market due to the growing geriatric population and innovative medical technology adoption.

Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2023 to 2030 due to the rising health awareness among the people and increasing demand for advanced medical technology.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Competitive Landscape and RNAi Therapeutics Market Share Analysis

The RNAi therapeutics market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to RNAi therapeutics market.

Some of the major players operating in the RNAi therapeutics market are:

  • Quark Software Inc. (U.S.)
  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • Rexahn Pharmaceuticals, Inc. (U.S.)
  • Silence Therapeutics (U.K.)
  • Arbutus Biopharma (U.S.)
  • Benitec Biopharma (Australia)
  • GSK plc (U.K.)
  • OLIX PHARMACEUTICALS, INC. (South Korea)
  • Sanofi (France)
  • Alnylam Pharmaceuticals, Inc. (U.S.)
  • Moderna Inc. (U.S.)
  • Ionis Pharmaceuticals (U.S.)

Research Methodology: Global RNAi Therapeutics Market

Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please request an analyst call or can drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Customization Available

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.


SKU-

Please fill in the below form for detailed Table of Content

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Table

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Figure

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for Infographics

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Research Methodology:

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Please fill in the below form for Research Methodology

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Customization Available:

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Please fill in the below form for Available Customization

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Get online access to the report on the World's First Market Intelligence Cloud

  • Interactive Data Analysis Dashboard
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
  • Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Request for Demo

FREQUENTLY ASK QUESTIONS

The RNAi Therapeutics Market will be worth USD 1645.76 million in the forecast period by 2030.
The RNAi Therapeutics Market growth rate is 9.3% during the forecast period by 2030.
Rising cases of chronic diseases and increasing collaborative activities are the growth drivers of the RNAi Therapeutics Market.
The molecule type, application, route of administration and end-user are the factors on which the RNAi Therapeutics Market research is based.
Major companies in the RNAi Therapeutics Market are Quark Software Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Rexahn Pharmaceuticals, Inc. (U.S.), Silence Therapeutics (U.K.), Arbutus Biopharma (U.S.), Benitec Biopharma (Australia), GSK plc (U.K.), OLIX PHARMACEUTICALS, INC. (South Korea), Sanofi (France), Alnylam Pharmaceuticals, Inc. (U.S.), Moderna Inc. (U.S.), Ionis Pharmaceuticals (U.S.).
Free Sample Report

CHOOSE LICENCE TYPE

  • 7000.00
  • 4800.00
  • 3000.00
  • 8000.00
  • 12000.00

Why Choose Us

Industry Coverage

DBMR works across the globe in multiple industries which equip us with knowledge across verticals and provide our clients with insights not only from their industry but how other industries will impact their ecosystem.

Regional Coverage

Coverage of Data Bridge is not restricted to developed or emerging economies. We work across the globe covering the largest array of countries where no other market research or business consulting firm has ever conducted research; creating growth opportunities for our clients in areas which are still unknown.

Technology Coverage

In today’s world, technology drives the market sentiment, so our vision is to provide our clients insights not only for developed technologies but upcoming and disrupting technological changes throughout the product lifecycle by enabling them with unforeseen opportunities in the market which will create disruption in their industry. This leads to innovation and our clients to come out as winners.

Goal Oriented Solutions

DBMR goal is to help our clients achieve their goals through our solutions; hence we formatively create the most appropriate solutions for our client needs, saving time and efforts for them to drive their grand strategies.

Unparallel Analyst Support

Our analysts take pride in our clients’ success. Unlike others, we believe in working along our clients to achieve their goals with 24 hours analyst support determining the correct needs and inspire innovation through service.

Banner

Client Testimonials